Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003136806 | SCV003821428 | uncertain significance | not provided | 2022-04-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004963560 | SCV005504987 | uncertain significance | Inborn genetic diseases | 2024-09-02 | criteria provided, single submitter | clinical testing | The c.1492A>C (p.I498L) alteration is located in exon 13 (coding exon 12) of the SLC4A1 gene. This alteration results from a A to C substitution at nucleotide position 1492, causing the isoleucine (I) at amino acid position 498 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005011242 | SCV005640059 | uncertain significance | BLOOD GROUP--SWANN SYSTEM; BLOOD GROUP--WALDNER TYPE; BLOOD GROUP--FROESE; BLOOD GROUP--WRIGHT ANTIGEN; Southeast Asian ovalocytosis; Hereditary spherocytosis type 4; BLOOD GROUP--DIEGO SYSTEM; Cryohydrocytosis; Autosomal dominant distal renal tubular acidosis; Renal tubular acidosis, distal, 4, with hemolytic anemia; Malaria, susceptibility to | 2024-04-23 | criteria provided, single submitter | clinical testing |